CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ying Wang

Criteria

Inclusion Criteria:

1. Diagnosed CD7 positive relapsed/refractory hematological malignancies.

2. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%;

3. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%;

4. The estimated survival time is more than 3 months;

5. Eastern cooperative oncology group (ECOG) performance status of 0 to 2

6. The patients or their legal guardians voluntarily participated in the trial and signed the informed consent.

Exclusion Criteria:

1. Patients with history of epilepsy or other central nervous system diseases;

2. Patients with prolonged QT or severe heart disease;

3. Pregnant or lactating women

4. Patients with uncontrolled active infection.

5. Positive for any of the following etiological tests: HIV, HBV, HCV

6. Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial